Manufacturer
GLAXO WELLCOME S.A.
Contents
Rosiglitazone maleate
Indication
Type 2 DM (monotherapy or combination therapy).
Instruction
May be taken with or without food.
Drug interaction
May increase plasma levels w/ CYP2C8 inhibitors (e.g. ketoconazole, trimethoprim, gemfibrozil). May decrease plasma levels w/ rifampicin. May increase risk of heart failure and oedema w/ NSAIDs. Potentially Fatal: Increased risk of CHF and MI w/ insulin and nitrates.
Malaysia
